Nov 23, 2022
Lytix Biopharma held a CMD November 22nd, 2022 - webcast replay is available
Lytix Biopharma held a Capital Markets Day primarily focusing on the core and versatility of the Lytix Technology Platform and selected parts of our clinical development program. The CMD was a live event (open for physical attendance at Hotel Continental in Oslo, Norway) and a live webcast.
The program included presentations and Q&A with
Øystein Rekdal, CEO of Lytix - What makes Lytix' immuno-oncology technology platform stand out as unique?
Niels Junker, Chief Physician at Herlev Hospital and investigator at the ATLAS-IT-04 proof-of-concept study - Investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma – a pilot study.
Aurélien Marabelle, Professor of Clinical Immunology, Université Paris Saclay and an internationally recognized expert on intratumoral cancer treatment - Liver cancer: Current treatment modalities and how oncolytic molecules could play an integral role in future liver cancer treatment.
Stephen Worsley, CBO of Lytix - The commercial versatility of oncolytic molecules: What can LTX-315/401 bring to the immuno-oncology table/offer to the pharmaceutical industry.
The webcast replay is available here
For further information, please contact Ole Peter Nordby, Head of IR & Communication Manager (ole.peter.nordby@lytixbiopharma.com)